MA51524A - Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques - Google Patents
Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiquesInfo
- Publication number
- MA51524A MA51524A MA051524A MA51524A MA51524A MA 51524 A MA51524 A MA 51524A MA 051524 A MA051524 A MA 051524A MA 51524 A MA51524 A MA 51524A MA 51524 A MA51524 A MA 51524A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- compounds
- treatment
- methods
- diseases involving
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862613931P | 2018-01-05 | 2018-01-05 | |
US201862758264P | 2018-11-09 | 2018-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51524A true MA51524A (fr) | 2020-11-11 |
Family
ID=65411925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051524A MA51524A (fr) | 2018-01-05 | 2019-01-04 | Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques |
Country Status (18)
Country | Link |
---|---|
US (2) | US10933069B2 (fr) |
EP (1) | EP3735297A1 (fr) |
JP (2) | JP7356450B2 (fr) |
KR (1) | KR20200121800A (fr) |
CN (1) | CN111989137A (fr) |
AU (1) | AU2019205325A1 (fr) |
BR (1) | BR112020013672A2 (fr) |
CA (1) | CA3088858A1 (fr) |
CL (1) | CL2020001797A1 (fr) |
CR (1) | CR20200334A (fr) |
EC (1) | ECSP20046463A (fr) |
IL (1) | IL275754A (fr) |
MA (1) | MA51524A (fr) |
MX (1) | MX2020007060A (fr) |
PE (1) | PE20211305A1 (fr) |
PH (1) | PH12020551043A1 (fr) |
TW (1) | TWI820077B (fr) |
WO (1) | WO2019136298A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018227132A1 (fr) * | 2017-06-09 | 2018-12-13 | Rhode Island Council On Postsecondary Education | Composés liés et autres composés activés par ph |
US10633383B2 (en) | 2018-01-05 | 2020-04-28 | Ac Immune Sa | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates |
EP3996749A1 (fr) | 2019-07-10 | 2022-05-18 | Cybrexa 3, Inc. | Conjugués peptidiques d'agents de ciblage de microtubules en tant qu'agents thérapeutiques |
WO2021007435A1 (fr) | 2019-07-10 | 2021-01-14 | Cybrexa 2, Inc. | Conjugués peptidiques de cytotoxines servant d'agents thérapeutiques |
CN112939966B (zh) * | 2019-12-10 | 2023-03-24 | 武汉光谷亚太医药研究院有限公司 | 嘧啶衍生物、其制备及应用 |
WO2021150792A1 (fr) | 2020-01-21 | 2021-07-29 | Micurx Pharmaceuticals, Inc. | Nouveaux composés et composition pour la thérapie ciblée de cancers associés au rein |
CN111285936A (zh) * | 2020-03-11 | 2020-06-16 | 北京双赢科创生物科技有限公司 | 靶向肿瘤的酸性敏感纳米肽段及其应用 |
CR20230378A (es) | 2021-01-08 | 2023-10-27 | Cybrexa 2 Inc | Proceso para preparar un resto enlazador de conjugados |
WO2022155172A1 (fr) | 2021-01-13 | 2022-07-21 | Cybrexa 3, Inc. | Conjugués peptidiques d'agents thérapeutiques |
CN115137818B (zh) * | 2021-03-31 | 2023-06-27 | 华南师范大学 | 谷胱甘肽激活的光敏剂-化疗药一体化分子前药及其应用 |
WO2022232808A1 (fr) | 2021-04-29 | 2022-11-03 | Cybrexa 2, Inc. | Schémas posologiques de conjugués peptidiques d'inhibiteurs de la topoisomérase i |
KR102677962B1 (ko) * | 2022-03-02 | 2024-06-25 | 고려대학교 산학협력단 | 루카파립의 개선된 제조방법 |
CN116640229B (zh) * | 2023-04-10 | 2024-01-30 | 中国人民解放军总医院第五医学中心 | 一种低pH靶向性CAR-T细胞的构建及应用 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP866A (en) | 1995-08-02 | 2000-08-17 | Newcastle Univ Ventures Limited | Benzimidazole compounds. |
MY132496A (en) * | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
TR200101239T2 (tr) | 1998-11-03 | 2001-11-21 | Basf Aktiengesellschaft | İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları |
OA11749A (en) * | 1999-01-11 | 2005-07-19 | Agouron Pharma | Tricyclic inhibitors of poly(adp-ribose)polymerases. |
DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
CA2396513A1 (fr) | 1999-12-13 | 2001-06-14 | Yanzhi Zhang | Promedicaments de phosphate pseudomycine |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GEP20074230B (en) | 2002-03-20 | 2007-11-12 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
JP2006522088A (ja) | 2003-03-31 | 2006-09-28 | ファイザー・インク | ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩 |
ES2339663T3 (es) * | 2003-07-25 | 2010-05-24 | Cancer Research Technology Limited | Inhibidores de parp triciclicos. |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
PL1684736T3 (pl) | 2003-12-01 | 2012-01-31 | Kudos Pharm Ltd | Inhibitory naprawy DNA w leczeniu raka |
KR20080097497A (ko) | 2004-09-22 | 2008-11-05 | 화이자 인코포레이티드 | 폴리(adp-리보오스) 폴리머라제 억제제의 제조 방법 |
MX2007003314A (es) | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
WO2006033007A2 (fr) | 2004-09-22 | 2006-03-30 | Pfizer Inc. | Formules polymorphes et amorphes de sel de phosphate de 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
ES2399267T3 (es) | 2005-01-18 | 2013-03-27 | The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations | Suministro selectivo de moléculas al interior de las células o marcación de células en zonas enfermas de tejidos usando un péptido transmembrana sensible a su entorno |
WO2007041357A1 (fr) | 2005-09-29 | 2007-04-12 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides a substitution phenyle en position 2, utilises comme inhibiteurs de la parp |
EP2338487B1 (fr) * | 2006-01-17 | 2013-09-11 | Abbott Laboratories | Thérapie combinée comportant des inhibiteurs de PARP |
UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
RS51780B (en) | 2007-01-10 | 2011-12-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | INDASOLS SUBSTITUTED BY AMIDE AS INHIBITORS OF POLY (ADP-Ribose) POLYMERASES (PARP) |
WO2008114114A2 (fr) | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Inhibiteurs de poly(adp-ribose)polymérases pour le traitement d'une condition ophtalmique |
US8067613B2 (en) | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
JP5579170B2 (ja) * | 2008-06-05 | 2014-08-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Dgat阻害剤とppar作動薬を含有する薬剤組み合わせ物 |
US9353140B2 (en) | 2009-11-25 | 2016-05-31 | Academia Sinica | BQC-G, a tumor-selective anti-cancer prodrug |
SI2534153T1 (sl) | 2010-02-12 | 2017-01-31 | Pfizer Inc. | Soli in polimorfi 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6H-azepino (5,4,3-cd)indol-6-ona |
CA3032185C (fr) | 2010-07-13 | 2021-08-03 | Council on Postsecondary Education, State of Rhode Island and Providence Plantations | Composition respectueuse de l'environnement renfermant un peptide declenche par le ph et utilisation associee |
CA2808313C (fr) * | 2010-08-13 | 2021-04-13 | Rhode Island Board Of Governors For Higher Education | Liposomes renfermant des polypeptides de peptide d'insertion a faible ph (phlip) |
TWI727919B (zh) | 2013-12-19 | 2021-05-21 | 美商西雅圖遺傳學公司 | 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物 |
WO2015108986A1 (fr) | 2014-01-16 | 2015-07-23 | Clovis Oncology, Inc. | Utilisation d'inhibiteurs de parp pour traiter des patients atteints de cancer du sein ou de l'ovaire présentant une perte d'hétérozygotie |
WO2016004043A1 (fr) | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Conjugués ciblés, particules et préparations associées |
CN106794185A (zh) | 2014-08-22 | 2017-05-31 | 克洛维斯肿瘤有限公司 | Rucaparib的高剂量强度片剂 |
WO2016057398A1 (fr) * | 2014-10-07 | 2016-04-14 | Immunomedics, Inc. | Utilisation néoadjuvante de conjugués anticorps-médicaments |
MA43354A (fr) * | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
LT3380486T (lt) | 2015-11-24 | 2020-05-11 | Theravance Biopharma R&D Ip, Llc | Jak inhibitoriaus junginio provaistai, skirti virškinimo trakto uždegiminės ligos gydymui |
US20170267727A1 (en) | 2016-03-04 | 2017-09-21 | Lehigh University | Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors |
GB201608885D0 (en) * | 2016-05-20 | 2016-07-06 | Univ Birmingham | Treatment |
WO2017210608A1 (fr) | 2016-06-02 | 2017-12-07 | Yale University | Compositions et procédés de ciblage et de traitement de tumeurs déficientes en recombinaison homologue |
CN110312549B (zh) * | 2016-12-19 | 2021-06-29 | 莫尔豪斯医学院 | 用于通过抑制外泌体释放来治疗疾病的组合物和方法 |
WO2018227132A1 (fr) | 2017-06-09 | 2018-12-13 | Rhode Island Council On Postsecondary Education | Composés liés et autres composés activés par ph |
CN109232719B (zh) | 2018-09-21 | 2021-06-29 | 中国科学院理化技术研究所 | 一种pH响应的抗菌肽及其制备方法和应用 |
-
2019
- 2019-01-04 AU AU2019205325A patent/AU2019205325A1/en active Pending
- 2019-01-04 MA MA051524A patent/MA51524A/fr unknown
- 2019-01-04 CR CR20200334A patent/CR20200334A/es unknown
- 2019-01-04 CA CA3088858A patent/CA3088858A1/fr active Pending
- 2019-01-04 WO PCT/US2019/012413 patent/WO2019136298A1/fr unknown
- 2019-01-04 PE PE2020000907A patent/PE20211305A1/es unknown
- 2019-01-04 MX MX2020007060A patent/MX2020007060A/es unknown
- 2019-01-04 KR KR1020207022639A patent/KR20200121800A/ko active Search and Examination
- 2019-01-04 TW TW108100452A patent/TWI820077B/zh active
- 2019-01-04 BR BR112020013672-7A patent/BR112020013672A2/pt unknown
- 2019-01-04 EP EP19705248.3A patent/EP3735297A1/fr active Pending
- 2019-01-04 CN CN201980012818.6A patent/CN111989137A/zh active Pending
- 2019-01-04 US US16/240,438 patent/US10933069B2/en active Active
- 2019-01-04 JP JP2020557122A patent/JP7356450B2/ja active Active
-
2020
- 2020-06-30 IL IL275754A patent/IL275754A/en unknown
- 2020-07-03 PH PH12020551043A patent/PH12020551043A1/en unknown
- 2020-07-03 CL CL2020001797A patent/CL2020001797A1/es unknown
- 2020-08-04 EC ECSENADI202046463A patent/ECSP20046463A/es unknown
- 2020-10-28 US US17/082,992 patent/US20210299137A1/en active Pending
-
2023
- 2023-09-22 JP JP2023158930A patent/JP2024009819A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7356450B2 (ja) | 2023-10-04 |
JP2021510173A (ja) | 2021-04-15 |
TW201938540A (zh) | 2019-10-01 |
KR20200121800A (ko) | 2020-10-26 |
CN111989137A (zh) | 2020-11-24 |
BR112020013672A2 (pt) | 2020-12-01 |
US20190209580A1 (en) | 2019-07-11 |
EP3735297A1 (fr) | 2020-11-11 |
AU2019205325A1 (en) | 2020-08-13 |
US20210299137A1 (en) | 2021-09-30 |
US10933069B2 (en) | 2021-03-02 |
PH12020551043A1 (en) | 2021-09-06 |
TWI820077B (zh) | 2023-11-01 |
CA3088858A1 (fr) | 2019-07-11 |
JP2024009819A (ja) | 2024-01-23 |
ECSP20046463A (es) | 2020-12-31 |
IL275754A (en) | 2020-08-31 |
MX2020007060A (es) | 2020-11-11 |
CL2020001797A1 (es) | 2021-01-29 |
PE20211305A1 (es) | 2021-07-20 |
CR20200334A (es) | 2021-03-09 |
WO2019136298A1 (fr) | 2019-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51524A (fr) | Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques | |
MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
MA55974A (fr) | Composés triaryles pour le traitement de maladies pd-l1 | |
JOP20210154B1 (ar) | مثبطات kif18a | |
MX2021007104A (es) | Inhibidores de kif18a. | |
MA41841A (fr) | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs | |
MA50763A (fr) | Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires | |
MA51418A (fr) | Inhibiteurs de glycolate oxydase pour le traitement de maladies | |
MA46585A (fr) | Méthodes de traitement de l'atrophie musculaire et des maladies osseuses faisant appel à de nouvelles protéines hybrides piégeant le ligand d'actriib | |
MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
IL276383A (en) | Treatment of ophthalmological diseases | |
MA56412A (fr) | Thérapie par l'arn messager pour le traitement des maladies articulaires | |
MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
MA51738A (fr) | Composés pour le traitement de la douleur | |
MA55604A (fr) | Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra | |
MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
MA52415A (fr) | Dérivés de triazine pour le traitement de maladies associées à des neurotrophines | |
EA201100462A1 (ru) | Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств | |
MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
MA54741A (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
MA55144A (fr) | Composés naphthyridinone-aniline destinés au traitement d'affections de la peau |